CORRESP

0001193125-20-187257.txt : 20201211 0001193125-20-187257.hdr.sgml : 20201211 20200706060859 ACCESSION NUMBER: 0001193125-20-187257 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20200706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 CORRESP 1 filename1.htm CORRESP

LOGO

DANIEL M. MILLER

Partner

(604) 630-5199

FAX (604) 687-8504

miller.dan@dorsey.com

July 6, 2020

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

USA

Attention: Division of Corporation Finance, Office of Life Sciences

Re:

InMed Pharmaceuticals Inc.

Amendment No. 1 to Registration Statement on Form S-1

Submitted June 19, 2020

CIK No. 0001728328

Dear Sirs and Mesdames:

On behalf of our client, InMed Pharmaceuticals Inc. (the “Company”), and pursuant to the Securities Act of 1933, as amended (the “Act”), and the rules and regulations thereunder, we transmit for your review the Company’s responses, as we have been informed by the Company, to the Staff’s letter of comment, dated June 26, 2020 (the “Comment Letter”), in respect of the above noted registration statement. The Company’s response below is keyed to the heading and comment number contained in the Comment Letter.

Registration Statement on Form S-1 filed on June 19, 2020

Business

Our Product Candidates and Technologies

Key Milestones, page 79

1.

We note your response to comment 3. It appears that your Collaborative Research Agreement with the University of British Columbia is material to your business. Please disclose in the Summary section that such agreement may be terminated by either party upon 30 days’ written notice, as referenced on page 78.

The requested revisions have been made in the noted section, as well as to a related risk factor in the section entitled “Risk Factors”, of Amendment No. 1 to the Registration Statement on Form S-1.

DORSEY & WHITNEY LLP · WWW.DORSEY.COM · T 604.687.5151 · F 604.687.8504

SUITE 1605 · 777 DUNSMUIR STREET · P.O. BOX 10444 · PACIFIC CENTRE · VANCOUVER, BRITISH COLUMBIA CANADA V7Y 1K4

USA CANADA EUROPE ASIA

LOGO

U.S. Securities and Exchange Commission

July 6, 2020

Page 2

The Company has also made additional revisions in Amendment No. 1 to the Registration Statement on Form S-1, in order to reflect the Company’s recently completed share consolidation and certain other matters.

* * *

Should you have further comments or require further information, or if any questions should arise in connection with this submission, please call the undersigned at (604) 630-5199. You also may email me at miller.dan@dorsey.com or fax me at (604) 687-8504.

Yours truly,

/s/ Daniel M. Miller

Daniel M. Miller

cc:	Eric A. Adams

Bruce S. Colwill

InMed Pharmaceuticals Inc.

DORSEY & WHITNEY LLP

GRAPHIC 2 g935310pg1.jpg GRAPHIC begin 644 g935310pg1.jpg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g935310pg2.jpg GRAPHIC begin 644 g935310pg2.jpg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end